Chen-Ching Lin

Prof. Chen-Ching Lin


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2025 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
KFKang-Chen Fan
Kang-Chen Fan
CLChen-Ching Lin
Chen-Ching Lin
YCYen-Ling Chiu
Yen-Ling Chiu
Seong-Ho KohSeong-Ho Koh
Seong-Ho Koh
YLYi-Chien Liu
Yi-Chien Liu
YCYi-Fang Chuang
Yi-Fang Chuang
Emerging evidence highlights the bidirectional communication between the gut microbiota and the brain, suggesting a potential role for gut dysbiosis in Alzheimer’s disease (AD) pathology and cognitive decline. Existing literature on gut microbiota lacks species-level insights. This study investigates gut microbiota alterations in mild cognitive impairment (MCI), focusing on their association with comprehensive AD biomarkers, including amyloid burden, tau pathology, neurodegeneration, and cognitive performance. We analyzed fecal samples from 119 individuals with MCI and 320 cognitively normal controls enrolled in the Taiwan Precision Medicine Initiative on Cognitive Impairment and Dementia cohort. Shotgun metagenomic sequencing was conducted with taxonomic profiling using MetaPhlAn4. Amyloid burden and plasma pTau181 were quantified via PET imaging and Simoa assays, respectively, while APOE genotyping was performed using TaqMan assays. Microbial diversity, differential abundance analysis, and correlation mapping with neuropsychological and neuroimaging measures were conducted to identify gut microbiota species signatures associated with MCI and AD biomarkers. We identified 59 key microbial species linked to MCI and AD biomarkers. Notably, species within the same genera, such as Bacteroides and Ruminococcus, showed opposing effects, while Akkermansia muciniphila correlated with reduced amyloid burden, suggesting a protective role. Functional profiling revealed microbial pathways contributing to energy metabolism and neuroinflammation, mediating the relationship between gut microbes and brain health. Co-occurrence network analyses demonstrated complex microbial interactions, indicating that the collective influence of gut microbiota on neurodegeneration. Our findings challenge genus-level microbiome analyses, revealing species-specific modulators of AD pathology. This study highlights gut microbial activity as a potential therapeutic target to mitigate cognitive decline and neurodegeneration.

23 May 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
YCYi-Fang Chuang
Yi-Fang Chuang
KFKang-Chen Fan
Kang-Chen Fan
YSYin-Yuan Su
Yin-Yuan Su
MWMing-Fong Wu
Ming-Fong Wu
YCYen-Ling Chiu
Yen-Ling Chiu
CLChen-Ching Lin
Chen-Ching Lin
With the increasing prevalence of age-related chronic diseases burdening healthcare systems, there is a pressing need for innovative management strategies. Our study focuses on the gut microbiota, essential for metabolic, nutritional, and immune functions, which undergoes significant changes with aging. These changes can impair intestinal function, leading to altered microbial diversity and composition that potentially influence health outcomes and disease progression. Using advanced metagenomic sequencing, we explore the potential of personalized probiotic supplements in 297 older adults by analyzing their gut microbiota. We identified distinctive Lactobacillus and Bifidobacterium signatures in the gut microbiota of older adults, revealing probiotic patterns associated with various population characteristics, microbial compositions, cognitive functions, and neuroimaging results. These insights suggest that tailored probiotic supplements, designed to match individual probiotic profile, could offer an innovative method for addressing age-related diseases and functional declines. Our findings enhance the existing evidence base for probiotic use among older adults, highlighting the opportunity to create more targeted and effective probiotic strategies. However, additional research is required to validate our results and further assess the impact of precision probiotics on aging populations. Future studies should employ longitudinal designs and larger cohorts to conclusively demonstrate the benefits of tailored probiotic treatments.

1 February 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YSYin-Yuan Su
Yin-Yuan Su
HHHsuan-Cheng Huang
Hsuan-Cheng Huang
YLYu-Ting Lin
Yu-Ting Lin
YCYi-Fang Chuang
Yi-Fang Chuang
SSSheh-Yi Sheu
Sheh-Yi Sheu
CLChen-Ching Lin
Chen-Ching Lin
The traditional process of developing new drugs is time-consuming and often unsuccessful, making drug repurposing an appealing alternative due to its speed and safety. Graph neural networks (GCNs) have emerged as a leading approach for predicting drug-disease associations by integrating drug and disease-related networks with advanced deep learning algorithms. However, GCNs generally infer association probabilities only for existing drugs and diseases, requiring network re-establishment and retraining for novel entities. Additionally, these methods often struggle with sparse networks and fail to elucidate the biological mechanisms underlying newly predicted drugs. To address the limitations of traditional methods, we developed HEDDI-Net, a heterogeneous embedding architecture designed to accurately detect drug-disease associations while preserving the interpretability of biological mechanisms. HEDDI-Net integrates graph and shallow learning techniques to extract representative diseases and proteins, respectively. These representative diseases and proteins are used to embed the input features, which are then utilized in a multilayer perceptron for predicting drug-disease associations. In experiments, HEDDI-Net achieves areas under the receiver operating characteristic curve of over 0.98, outperforming state-of-the-art methods. Rigorous recovery analyses reveal a median recovery rate of 73% for the top 100 diseases, demonstrating its efficacy in identifying novel target diseases for existing drugs, known as drug repurposing. A case study on Alzheimer's disease highlighted the model's practical applicability and interpretability, identifying potential drug candidates like Baclofen, Fluoxetine, Pentoxifylline and Phenytoin. Notably, over 40% of the predicted candidates in the clusters of commonly prescribed clinical drugs Donepezil and Galantamine had been tested in clinical trials, validating the model's predictive accuracy and practical relevance. HEDDI-NET represents a significant advancement by allowing direct application to new diseases and drugs without the need for retraining, a limitation of most GCN-based methods. Furthermore, HEDDI-Net provides detailed affinity patterns with representative proteins for predicted candidate drugs, facilitating an understanding of their physiological effects. This capability also supports the design and testing of alternative drugs that are similar to existing medications, enhancing the reliability and interpretability of potential repurposed drugs. The case study on Alzheimer's disease further underscores HEDDI-Net's ability to predict promising drugs and its applicability in drug repurposing.

20 July 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YSYin-Yuan Su
Yin-Yuan Su
YLYu-Ling Liu
Yu-Ling Liu
HHHsuan-Cheng Huang
Hsuan-Cheng Huang
CLChen-Ching Lin
Chen-Ching Lin
Background: The nuclear factor kappa B (NFκB) regulatory pathways downstream of tumor necrosis factor (TNF) play a critical role in carcinogenesis. However, the widespread influence of NFκB in cells can result in off-target effects, making it a challenging therapeutic target. Ensemble learning is a machine learning technique where multiple models are combined to improve the performance and robustness of the prediction. Accordingly, an ensemble learning model could uncover more precise targets within the NFκB/TNF signaling pathway for cancer therapy. Methods: In this study, we trained an ensemble learning model on the transcriptome profiles from 16 cancer types in the TCGA database to identify a robust set of genes that are consistently associated with the NFκB/TNF pathway in cancer. Our model uses cancer patients as features to predict the genes involved in the NFκB/TNF signaling pathway and can be adapted to predict the genes for different cancer types by switching the cancer type of patients. We also performed functional analysis, survival analysis, and a case study of triple-negative breast cancer to demonstrate our model's potential in translational cancer medicine. Results: Our model accurately identified genes regulated by NFκB in response to TNF in cancer patients. The downstream analysis showed that the identified genes are typically involved in the canonical NFκB-regulated pathways, particularly in adaptive immunity, anti-apoptosis, and cellular response to cytokine stimuli. These genes were found to have oncogenic properties and detrimental effects on patient survival. Our model also could distinguish patients with a specific cancer subtype, triple-negative breast cancer (TNBC), which is known to be influenced by NFκB-regulated pathways downstream of TNF. Furthermore, a functional module known as mononuclear cell differentiation was identified that accurately predicts TNBC patients and poor short-term survival in non-TNBC patients, providing a potential avenue for developing precision medicine for cancer subtypes. Conclusions: In conclusion, our approach enables the discovery of genes in NFκB-regulated pathways in response to TNF and their relevance to carcinogenesis. We successfully categorized these genes into functional groups, providing valuable insights for discovering more precise and targeted cancer therapeutics.

13 September 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
FHFu-Mei Hsieh
Fu-Mei Hsieh
SLSu-Ting Lai
Su-Ting Lai
MWMing-Fong Wu
Ming-Fong Wu
CLChen-Ching Lin
Chen-Ching Lin
MicroRNAs (miRNAs) are approximately 20–22 nucleotides in length, which are well known to participate in the post-transcriptional modification. The mature miRNAs were observed to be varied on 5′ or 3′ that raise another term—the isoforms of mature miRNAs (isomiRs), which have been proven not the artifacts and discussed widely recently. In our research, we focused on studying the 5′ isomiRs in lung adenocarcinoma (LUAD) in The Cancer Genome Atlas (TCGA). We characterized 75 isomiRs significantly associated with better prognosis and 43 isomiRs with poor prognosis. The 75 protective isomiRs can successfully distinguish tumors from normal samples and are expressed differently between patients of early and late stages. We also found that most of the protective isomiRs tend to be with downstream shift and upregulated compared with those with upstream shift, implying that a possible selection occurs during cancer development. Among these protective isomiRs, we observed a highly positive and significant correlation, as well as in harmful isomiRs, suggesting cooperation within the group. However, between protective and harmful, there is no such a concordance but conversely more negative correlation, suggesting the possible antagonistic effect between protective and harmful isomiRs. We also identified that two isomiRs miR-181a-3p|-3 and miR-181a-3p|2, respectively, belong to the harmful and protective groups, suggesting a bidirectional regulation of their originated archetype—miR-181a-3p. Additionally, we found that the protective isomiRs of miR-21-5p, which is an oncomiR, may be evolved as the tumor suppressors through producing isomiRs to hinder metastasis. In summary, these results displayed the characteristics of the protective isomiRs and their potential for developing the treatment of lung cancer.

15 February 2024 in Physical and Engineering Sciences in Medicine
Verified
Journal Article
Open access
PDF file
CHChieh-Chun Huang
Chieh-Chun Huang
SSShih-Hsien Sung
Shih-Hsien Sung
WWWei-Ting Wang
Wei-Ting Wang
YSYin-Yuan Su
Yin-Yuan Su
CHChi-Jung Huang
Chi-Jung Huang
HCHao-Min Cheng
Hao-Min Cheng
Hemodynamic parameters derived from pulse wave analysis have been shown to predict long-term outcomes in patients with heart failure (HF). Here we aimed to develop a deep-learning based algorithm that incorporates pressure waveforms for the identification and risk stratification of patients with HF. The first study, with a case–control study design to address data imbalance issue, included 431 subjects with HF exhibiting typical symptoms and 1545 control participants with no history of HF (non-HF). Carotid pressure waveforms were obtained from all the participants using applanation tonometry. The HF score, representing the probability of HF, was derived from a one-dimensional deep neural network (DNN) model trained with characteristics of the normalized carotid pressure waveform. In the second study of HF patients, we constructed a Cox regression model with 83 candidate clinical variables along with the HF score to predict the risk of all-cause mortality along with rehospitalization. To identify subjects using the HF score, the sensitivity, specificity, accuracy, F1 score, and area under receiver operating characteristic curve were 0.867, 0.851, 0.874, 0.878, and 0.93, respectively, from the hold-out cross-validation of the DNN, which was better than other machine learning models, including logistic regression, support vector machine, and random forest. With a median follow-up of 5.8 years, the multivariable Cox model using the HF score and other clinical variables outperformed the other HF risk prediction models with concordance index of 0.71, in which only the HF score and five clinical variables were independent significant predictors (p < 0.05), including age, history of percutaneous coronary intervention, concentration of sodium in the emergency room, N-terminal pro-brain natriuretic peptide, and hemoglobin. Our study demonstrated the diagnostic and prognostic utility of arterial waveforms in subjects with HF using a DNN model. Pulse wave contains valuable information that can benefit the clinical care of patients with HF.